Article Figures & Tables
Figures
- Figure 1:
Proportion of Escherichia coli and Klebsiella pneumoniae blood culture isolates that produced extended-spectrum β-lactamase (ESBL), altogether and in intensive care units (ICUs) and emergency departments (EDs), and proportion of ST131 clonal type within E. coli isolates that produced ESBL, 2006–2016.
- Figure 2:
Antimicrobial susceptibilities of Escherichia coli blood culture isolates, 2006–2016. (A): Extended-spectrum β-lactamase (ESBL) producers and non–ESBL-producers combined. (B): Non–ESBL-producers and ESBL producers separately.
Tables
- Table 1:
Proportion of Escherichia coli, Klebsiella pneumoniae, K. oxytoca and Proteus mirabilis blood culture isolates that produced extended-spectrum β-lactamase, including proportion of ST131 clonal type within E. coli isolates that produced extended-spectrum β-lactamase, 2006–2016
Organism Year; no. (%) of isolates p value* 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Escherichia coli 19/296 (6.4) 13/309 (4.2) 29/355 (8.2) 28/376 (7.4) 33/394 (8.4) 51/428 (11.9) 58/457 (12.7) 81/485 (16.7) 65/485 (13.4) 76/516 (14.7) 89/513 (17.3) < 0.001 Klebsiella pneumoniae 6/120 (5.0) 5/109 (4.6) 5/87 (5.7) 0/115 (0.0) 6/139 (4.3) 9/136 (6.6) 4/129 (3.1) 8/162 (4.9) 11/154 (7.1) 9/191 (4.7) 18/196 (9.2) 0.04 K. oxytoca 0/4 (0.0) 3/20 (15.0) 3/23 (13.0) 1/25 (4.0) 1/22 (4.5) 0/18 (0.0) 1/23 (4.3) 0/23 (0.0) 1/30 (3.3) 0/40 (0.0) 0/33 (0.0) 0.002 Proteus mirabilis 0/23 (0.0) 0/30 (0.0) 0/26 (0.0) 0/27 (0.0) 0/34 (0.0) 0/31 (0.0) 2/38 (5.3) 0/30 (0.0) 0/32 (0.0) 0/36 (0.0) 1/35 (2.8) 0.3 ST131 clonal type among ESBL-producing E. coli 6/19 (31.6) 8/13 (61.5) 20/28 (71.4) 16/26 (61.5) 19/32 (59.4) 27/46 (58.7) 36/58 (62.1) 54/80 (67.5) 40/65 (61.5) 48/76 (63.2) 65/89 (73.0) 0.03 Note: ESBL = extended-spectrum β-lactamase.
↵* For the trend observed between 2006 and 2016 (χ2 test for trend).
- Table 2:
Proportion of Escherichia coli blood culture isolates that produced extended-spectrum β-lactamase in intensive care units and emergency departments, 2006–2016
Setting Year; no. (%) of isolates p value* 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Intensive care unit 1/9 (11.1) 1/17 (5.9) 1/10 (10.0) 2/19 (10.5) 2/26 (7.7) 2/18 (11.1) 5/25 (20.0) 6/32 (18.8) 7/28 (25.0) 7/39 (17.9) 8/31 (25.8) 0.02 Emergency department 6/180 (3.3) 4/172 (2.3) 14/206 (6.8) 13/201 (6.5) 14/128 (10.9) 28/264 (10.6) 35/272 (12.9) 44/287 (15.3) 27/298 (9.1) 31/300 (10.3) 47/318 (14.8) < 0.001 ↵* For the trend observed between 2006 and 2016 (χ2 test for trend.)
- Table 3:
Susceptibility to selected antimicrobial agents of all Escherichia coli isolates, E. coli that did not produce extended-spectrum β-lactamase and E. coli that produced extended-spectrum β-lactamase, 2016
Agent % of isolates susceptible p value* All Escherichia coli
n = 513Non–ESBL-producing Escherichia coli
n = 424ESBL-producing Escherichia coli
n = 89Ciprofloxacin 64.3 75.7 10.1 < 0.001 Trimethoprim–sulfamethoxazole 66.9 73.8 33.7 < 0.001 Tobramycin 80.5 87.3 48.3 < 0.001 Gentamicin 85.4 88.2 71.9 < 0.001 Ceftriaxone 81.3 98.3 0.0 < 0.001 Ertapenem 99.8 100.0 98.9 0.2 Meropenem/imipenem 100.0 100.0 100.0 – Note: ESBL = extended spectrum β-lactamase.
↵* For the difference in susceptibility between non–ESBL-producing E. coli and ESBL-producing E. coli (Fisher exact test).
In this issue
Article tools
Related Articles
Cited By...
- No citing articles found.